Agios Pharmaceuticals Inc... (AGIO)
NASDAQ: AGIO
· Real-Time Price · USD
36.18
-1.27 (-3.39%)
At close: Aug 19, 2025, 3:59 PM
36.22
0.11%
After-hours: Aug 19, 2025, 06:09 PM EDT
-3.39% (1D)
| Bid | 35.64 |
| Market Cap | 2.1B |
| Revenue (ttm) | 40.88M |
| Net Income (ttm) | 650.08M |
| EPS (ttm) | 11.29 |
| PE Ratio (ttm) | 3.2 |
| Forward PE | -4.97 |
| Analyst | Buy |
| Ask | 38 |
| Volume | 484,008 |
| Avg. Volume (20D) | 746,762 |
| Open | 37.48 |
| Previous Close | 37.45 |
| Day's Range | 35.92 - 37.73 |
| 52-Week Range | 23.42 - 62.58 |
| Beta | 0.80 |
About AGIO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AGIO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AGIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Agios Pharmaceuticals Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+3.31%
AGIO stock has given up its prior gain. Agios Phar...
Unlock content with
Pro Subscription
2 weeks ago
+3.31%
Agios Pharmaceuticals shares are trading higher amid reports of Pyrukynd patient deaths.
2 weeks ago · seekingalpha.com
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call TranscriptAgios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Ch...
